TOP ONCOLOGY CRO
EXPERTS IN CLINICAL ONCOLOGY
QUALITY ONCOLOGY TRIAL MONITORING
home blog news careers français contact
QUALITY ONCOLOGY TRIAL MANAGEMENT



The Reverse Feasibility Program™

A Novel CRO Approach to Site Selection
& Patient Recruitment

Reverse Feasibility Program for 50% faster site start-up.A revolutionary approach to feasibility assessment that accelerates study start-up by matching your protocol with the current study needs of motivated and pre-qualified North American sites.

How it works...


Oncology Clinical Trial News

Scimega launches Canadian expansion of an ongoing Phase 1 / 2 Study of an HSP90 Inhibitor Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Scimega launches Canadian expansion of an ongoing Phase 1b, open-label study to assess the safety and tolerability of an orally active, reversible and selective HER2 inhibitor combined with trastuzumab emtansine (TDM1) in HER2+metastatic breast cancer..

Scimega launches Canadian Phase II exploratory study to identify biomarkers predictive of clinical response to an oral multi-kinase inhibitor in patients with metastatic colorectal cancer who have failed first-line therapy.

See all news...

Upcoming Scimega Events

American Society of Hematology (ASH) 56th Annual Meeting

Dec. 6-8, 2014 in San Francisco

Clinical Operations in Oncology Trials – West Coast

April 17-18, 2015 in Burlingame, CA

AACR Annual Meeting (American Association for Cancer Research)

April 18-22, 2015 in Philadelphia

See all upcoming events...


Latest Podcast

Centralized IRB Review for Multi-Centre Clinical Trials

An Interview with Janet Manzo – Executive Director, Ontario Cancer Research Ethics Board (OCREB)
Listen...



Copyright © Scimega Research Inc. 2014. All rights reserved.
Privacy Policy

Oncology CRO   Clinical Trial Monitoring   Clinical Trial Management   Oncology Community